Two highly relevant, recent @Nature papers have been published to deepen our understanding of the potential benefit of imatinib for the treatment of #Covid_19:
https://doi.org/10.1038/s41586-020-2901-9
and https://doi.org/10.1038/s41586-020-03065-y

Team at University of Maryland, Baltimore recently published their protocol for study of oral imatinib in hospitalized adults with COVID-19

https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04819-9#MOESM1

Really pleased to announce that the CounterCOVID study https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001236-10/NL has today achieved 50% inclusion
#Clinicaltrial #COVID19